tbuckley/cabot-search huggingface dataset:
Abstract 014: Bone Marrow Mesenchymal Stromal Cells Rescue Cardiac Function In Streptozotocin-induced Diabetic Rats
Authors: Emiliano Medei, Gustavo Monnerat Cahli, Mayra Trentin-Sonoda, Deivid Rodrigues, Bárbara Guerra, Gabriel Manso, Danielle Coutinho, Mauricio Cabral-da-Silva, Andrea Ferreira, Diorney Silva, José Nascimento, Regina dos Santos Goldenberg, Marcela Carneiro-Ramos, Antonio Campos de Carvalho
Journal: Circulation Research (2013)

Cardiac complications are one of the main causes of death in diabetes. Several studies have shown the anti-diabetic effects of bone marrow mesenchymal stromal cells (MSC). In the present study, we investigated whether MSC-transplantation can revert cardiac dysfunction in streptozotocin-induced diabetic rats and the immunoregulatory effects of MSC were examined. The rats were divided in three groups: Non-diabetic, Diabetic and Diabetic-Treated that received 5x106 MSC 4 weeks after establishment of diabetes. Four weeks after MSC-therapy, systemic metabolic parameters, immunological profile and cardiac function were assessed. MSC-transplantation was able to revert the hyperglycemia and body weight loss of the animals, while decreasing to control levels sera corticosterone and the proinflammatory cytokine CINC2 without restoring insulin and leptin plasma levels and oral glucose tolerance. Also, MSC-therapy improved electrical remodeling, shortening the QT and QTc in the ECG and the action potential duration of left ventricular myocytes. No arrhythmic events were observed after MSC-transplantation. MSC-therapy rescued the cardiac beta-adrenergic sensitivity by increasing beta-1 adrenergic receptor expression. Both alpha and beta cardiac AMPK and p-AMPK returned to baseline values after MSC-therapy. However, the total ERK1 and p-ERK1/2 were not different among groups. MSC-therapy reestablished the cardiac control levels of key proinflammatory cytokines/chemokines (IL-6, IL-18, CINC2, CINC3). However MSC-therapy did not modulate toll-like receptor signaling pathways. The results indicate that MSC-therapy was able to rescue cardiac impairment induced by diabetes, normalize cardiac AMPK subunit expression and activity, decrease corticosterone and glycemia and exert local (cardiac) and systemic immunoregulation.
Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents
Authors: Cindy L. Grines, Robert O. Bonow, Donald E. Casey, Timothy J. Gardner, Peter B. Lockhart, David J. Moliterno, Patrick O'Gara, Patrick Whitlow
Journal: Journal of the American College of Cardiology (2007)
Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.
Authors: Monica Khunger, Sagar Rakshit, Kurt Alex Schalper, Paul Elson, Nathan A. Pennell, James Stevenson, Vamsidhar Velcheti
Journal: Journal of Clinical Oncology (2016)

11603 Background: Drugs targeting the PD1/PD-L1 pathway show significant clinical activity across several tumors. However, a majority of patients (pts) do not respond to these agents. Biomarker assays to predict response is an active area of research however the predictive value of PD-L1 IHC assays is inconsistent across clinical trials. In this meta-analysis of clinical trials with PD1/PD-L1 targeted agents we evaluate the predictive value of PD-L1 IHC. Methods: We searched databases (PubMed, Medline, Cochrane) and major conference proceedings up until 01/2015 for clinical trials using PD1/PD-L1 inhibitors with reported PD-L1 biomarker data. Objective response rates (primary endpoint) from all phase I-III trials investigating Nivolumab, Pembrolizumab, Atezolimumab, Durvalumab and Avelumab for non-small cell lung cancer (NSCLC), melanoma and genitourinary cancers were collected. Odds ratios (OR) for response in PD-L1 (+) pts compared to PD-L1 (-) pts were calculated using the DerSimonian-Laird random effects model to combine trials (Table 1). Meta-analysis was performed as per the PRISMA guidelines. Results: 18 distinct trials (9 NSCLC; 4 melanoma, 3 renal cell carcinoma and 2 bladder cancer) with 2731 pts were identified. Except bladder cancer (only 2 trials and small number of pts) PD-L1 expression was predictive of favorable response across all tumor types (OR = 2.77; 95% CI (2.26-3.39)p < .001); with the largest effect being seen in NSCLC (OR = 3.33; 95% CI (2.52-4.40)p < .001). Based on several trials in NSCLC that simultaneously assessed different thresholds for defining PDL-1 positivity, 1%, 5% and 10%, using 5% as a cutoff appears to have maximum discrimination (OR = 2.72; 95% CI (1.27-5.81)p = .01). Conclusions: PD-L1 expression on tumor cells is a positive predictive marker for response with checkpoint inhibitors. Use of 5% tumor PD-L1 expression as a cutoff of PD-L1 expression may be optimal. Tumor No. trials OR (95% CI) P NSCLC 9 3.33 (2.52-4.40) < 0.001 Melanoma 4 2.28 (1.63-3.19) < 0.001 Renal Cell 3 2.35 (1.04-5.31) 0.04 Bladder 2 1.76 (0.54-5.72) 0.35 PDL-1 Cutoff 1% 3 2.10 (0.82-5.36) 0.12 5% 3 2.72 (1.27-5.81) 0.01 10% 3 2.48 (1.04-5.93) 0.04
Factors Influencing Prognosis of Bundle Branch Block Complicating Acute Antero-Septal Infarction
Authors: K. I. LIE, HEIN J. WELLENS, REINIER M. SCHUILENBURG, ANTON E. BECKER, DIRK DURRER
Journal: Circulation (1974)

Of 50 consecutive patients with bundle branch block (BBB) complicating acute antero-septal infarction, 37 died in hospital. Patients with BBB of delayed onset or BBB of short duration had a significantly lower mortality. His bundle recordings were made in 35 patients without pulmonary edema or shock at the time of appearance of BBB. Thirteen of 16 patients with prolonged H-V intervals died compared to nine of 19 with normal H-V intervals ( P &lt; 0.05). In patients with bifascicular block, 11 of 15 with prolonged H-V intervals developed complete A-V block compared to one of ten with normal H-V intervals ( P &lt; 0.005). Twenty-five of 33 patients with normal P-R intervals died compared to eight of 12 with first degree A-V block. Seven of 15 patients with prolonged H-V intervals had normal P-R intervals and four of these seven developed complete A-V block. We conclude that the length of P-R interval has no prognostic significance and is of limited value in predicting both prolonged H-V interval and development of complete A-V block. In contrast, His bundle recordings are of value in identifying patients with BBB complicating antero-septal infarction who are at immediate high risk for development of complete A-V block and death.
Impact of Total Pars Plana Vitrectomy on Postoperative Complications in Aphakic, Snap-On, Type 1 Boston Keratoprosthesis
Authors: Victor L. Perez, Ella H. Leung, Audina M. Berrocal, Thomas A. Albini, Jean Marie Parel, Guillermo Amescua, Eduardo C. Alfonso, Tayyeba K. Ali, Allister Gibbons
Journal: Ophthalmology (2017)
Obesity as self-regulation failure: A “disease of affluence” that selectively hits the less affluent?
Authors: Pier Luigi Sacco
Journal: Behavioral and Brain Sciences (2017)

Abstract An effect of the long-term cycle of industrial and post-industrial global development is the increasingly generalized access to abundant and diversified food sources. This poses a substantial problem of self-regulation that mainly affects the less affluent and whose failures may play an important role in the explanation of the increasing social incidence of overweight and obesity problems.
Somatic Mutational Landscape of AML with Inv(16) and t(8;21) Identifies Two Distinct Patterns in Relapse Tumors
Authors: Raman B. Sood, Nancy F Hansen, Frank X Donovan, Blake Carrington, Baishali Maskeri, Alice Young, Donna Bucci, Settara Chandrasekharaappa, James C Mullikin, Clara D. Bloomfield, Guido Marcucci, Paul Liu
Journal: Blood (2014)
Baseline demographics of neuroendocrine tumor patients presenting to seven National Comprehensive Cancer Network (NCCN) institutions: Development of a multi-institutional outcomes database.
Authors: Carrie C. Zornosa, Michael A. Choti, Sarah Bobiak, Matthew Kulke, James C. Yao, Emily K. Bergsland, Eric K. Nakakura, Mark Bloomston, Al B. Benson, Manisha H. Shah, Jonathan R. Strosberg
Journal: Journal of Clinical Oncology (2012)

e14551 Background: Diagnostic strategies, management paradigms, and clinical outcomes of patients with neuroendocrine tumors (NETs) are diverse and poorly characterized. The National Comprehensive Cancer Network (NCCN) created a comprehensive database to characterize patients treated for NETs at seven participating institutions. Preliminary results from the database are reported. Methods: Member IRB approval was obtained to identify patients at least 18 years of age presenting to each of seven NCCN institutions between 2004 and 2007 with pathologically confirmed newly or previously diagnosed NETs via hospital medical records. Eligible patients included those with carcinoid (any site); goblet cell or adenocarcinoid; composite carcinoid; poorly differentiated gastrointestinal small cell tumor; pancreatic NET; NET of unknown primary site; pheochromocytoma; and paraganglioma. Baseline demographic characteristics were summarized for this analysis. Results: Among the 2,798 patients identified with a NET diagnosis, patients most frequently presented with carcinoid tumor (53%), pancreatic NET (26%) and NET of unknown primary site (8%). Median age at diagnosis was 56 (SD=14). Fifty-three percent of patients were female. Most (86%) were Caucasian and 8% were African American. Thirty percent of patients were diagnosed with NET before presenting to the NCCN. Among these, the median time between initial NET diagnosis and presentation to the NCCN was 2 years (SD=6). Significant differences in provider specialty referral patterns were observed between institutions. The institutional point of entry for the majority of patients was medical oncology (institutional range: 17-93%) or surgery (institutional range: 3-62%). Conclusions: The baseline demographic characteristics of NET patients in this new database are consistent with those previously reported in population-based registries. The database will provide a valuable resource for further exploration of patterns of diagnosis, treatment, and consistency with established guidelines, as well as clinical outcomes in patients with this condition.
Successful Removal of a Myxoma from the Left Atrium
Authors: J. Gordon Scannell, William R. Brewster, Edward F. Bland
Journal: New England Journal of Medicine (1956)

WE are reporting herewith the surgical removal of a myxoma from the cavity of the left atrium. The procedure was carried out under hypothermia and represents the first successful case reported from this country and the third in the literature (Crafoord,1 in 1954, and Bigelow et al.,2 in 1955, having recorded previous cases).The presenting symptoms and signs, as is usual, were characteristic of mitral stenosis of high degree. This is important, for it is certain that as an increasing number of intracardiac operations are carried out greater numbers of tumors primary within the chambers of the heart will be . . .
Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014–2016: A cross-sectional study
Authors: Catherine F. Houlihan, Catherine R. McGowan, Steve Dicks, Marc Baguelin, David A. J. Moore, David Mabey, Chrissy h. Roberts, Alex Kumar, Dhan Samuel, Richard Tedder, Judith R. Glynn
Journal: PLoS Medicine (2017)

Healthcare and other front-line workers are at particular risk of infection with Ebola virus (EBOV). Despite the large-scale deployment of international responders, few cases of Ebola virus disease have been diagnosed in this group. Since asymptomatic or pauci-symptomatic infection has been described, it is plausible that infections have occurred in healthcare workers but have escaped being diagnosed. We aimed to assess the prevalence of asymptomatic or pauci-symptomatic infection, and of exposure events, among returned responders to the West African Ebola epidemic 2014-2016.
Citation classics in neuro-oncology: assessment of historical trends and scientific progress
Authors: Laureen D Hachem, Alireza Mansouri, Kyle Juraschka, Shervin Taslimi, Farhad Pirouzmand, Gelareh Zadeh
Journal: Neuro-Oncology (2017)

Citation classics represent the highest cited works in a field and are often regarded as the most influential literature. Analyzing thematic trends in citation classics across eras enables recognition of important historical advances within a field. We present the first analysis of the citation classics in neuro-oncology.The Web of Science database was searched using terms relevant to "neuro-oncology." Articles with >400 citations were identified and the top 100 cited articles were evaluated.The top 100 neuro-oncology citation classics consisted of 43 clinical studies (17 retrospective, 10 prospective, 16 randomized trials), 43 laboratory investigations, 8 reviews/meta-analyses, and 6 guidelines/consensus statements. Articles were classified into 4 themes: 13 pertained to tumor classification, 37 to tumor pathogenesis/clinical presentation, 6 to imaging, 44 to therapy (15 chemotherapy, 10 radiotherapy, 5 surgery, 14 new agents). Gliomas were the most common tumor type examined, with 70 articles. There was a significant increase in the number of citation classics in the late 1990s, which was paralleled by an increase in studies examining tumor pathogenesis, chemotherapy, and new agents along with laboratory and randomized studies.The majority of citation classics in neuro-oncology are related to gliomas and pertain to tumor pathogenesis and treatment. The rise in citation classics in recent years investigating tumor biology, new treatment agents, and chemotherapeutics may reflect increasing scientific interest in nonsurgical treatments for CNS tumors and the need for fundamental investigations into disease processes.
Abstract P177: Traditional Chinese Medication Qiliqiangxin Inhibits Cardiac Hypertrophy, Remodeling, and Dysfunction During Chronic Pressure Overload in Mice
Authors: Yunzeng Zou, Hui Gong, Li Lin, Ning Zhou, Lei Li, Yanyan Liang, Jian Wu, Jingmin Zhou, Junbo Ge
Journal: Circulation Research (2011)

Qiliqiangxin (QL), a traditional Chinese medicine, has been used in the treatment of chronic heart failure. However, whether QL can prevent cardiac hypertrophy and remodeling in the hypertensive is unknown. We here compared the effects of QL with Losartan on the development of cardiac hypertrophy in a mice model of pressure overload. Constriction of transverse aorta (TAC) or sham operation was imposed to C57B/L6 mice and QL (0.6mg/Kg/day), Losartan (13.4mg/Kg/day) or vehicle was then administrated to them. Cardiac hypertrophy, remodeling, functions and fibrosis were evaluated by echocardiography, catheterization, histology, and examination of specific gene expression and ERK phosphorylation. Local apoptosis, autophagy, TNF-α/IGF-1, angiotensin II type 1 receptor (AT1-R), and especially the proliferation of cardiomyocytes and phosphorylation of ErbB2 and ErbB4 were examined in vivo to elucidate the mechanisms. Two weeks later, TAC resulted in a significant cardiac hypertrophy in vehicle group, which was significantly suppressed in either QL or Losartan group. At the end of 4 weeks, QL treatment effectively abrogated TAC-induced the development of myocardial remodeling, dysfunction, fibrosis, and the increases in apoptosis, autophagy, TNF-α to IGF-1 ratio and AT1-R expression, which were comparable to Losartan treatment. However, QL, but not Losartan, enhanced proliferation of cardiomyocytes at 4 weeks after TAC, which was paralleled with dowregulation of C/EBP β , upregulation of CITED4 , and increases in ErbB2 and ErbB4 phosphorylation. Thus, QL inhibits myocardial inflammation and cardiomyocyte death, and promotes cardiomyocyte proliferation, leading to an ameliorated cardiac remodeling and function in a mice model of pressure overload. The possible mechanisms may involve inhibition of AT1-R and activation of ErbB receptors.
Abstract 193: Knockdown of Nucleosome Assembly Protein 1-Like 1 Promotes Dimethyl Sulfoxide-Induced Differentiation of P19CL6 Cells into Cardiomyocytes
Authors: Hui Gong, Lu Li, Yuan Yan, Yuanyuan Xue, Zhidan Chen, Guoliang Jiang, Guoping Zhang, Pengyuan Yang, Yunzeng Zou
Journal: Circulation Research (2012)

Various stem cell populations have the potential for cardiac repair and regeneration after transplanted into ischaemic injury heart. However, the low generation of new cardiomyocytes limits the clinic outcomes of stem cell therapy to a great extent. To develop novel strategies for enhancement the efficacy of stem cell differentiation into cardiomyocytes, we employed iTRAQ-coupled 2-D LC-MS/MS proteomics technology workflow to identify novel proteins which could promote P19CL6 cells differentiation into cardiomyocytes induced by dimethyl sulfoxide dimethyl sulfoxide (DMSO). 213 differentially expressed proteins were identified during differentiation of P19CL6 cells into cardiomyocytes. Nine proteins, Nap1L1, Sub1, Hspa5, Ywhaz, Sod1, Prdx2, Mif, Anp32a and Eef2, were confirmed by the real-time polymerase chain reaction (PCR) and western blotting respectively. iTRAQ ratios showed the down-regulation of nucleosome assembly protein 1-like 1 (Nap1L1) during the differentiation of P19CL6 cells into cardiomyocytes, which was confirmed by real-time PCR and western blot results. Further study indicated that knockdown of Nap1L1 expression promoted DMSO-induced cardiomyocytes differentiation in P19CL6 cells characterized by the increased expresison of cardiac specilal transcription factors (GATA4, MEF2C) and proteins (cTNT, ANP and BNP). This work suggested that Nap1L1 play an important role in DMSO-induced cardiomyocytes differentiation of P19CL6 cells. It also provides new insights and platforms for stem cell therapy in cardiovascular disease.
BONE MARROW TRANSPLANTATION IN THALASSEMIA
Authors: Claudio Giardini, M.D, Mariella Galimberti, M.D, Guido Lucarelli, M.D
Journal: Annual Review of Medicine (1995)

▪ Abstract Early trials of allogeneic bone marrow transplantation (BMT) for homozygous β-thalassemia and the analyses of results of transplantation in patients less than 16 years old have allowed us to identify three classes of risk based on the following criteria: (a) hepatomegaly, (b) presence of liver fibrosis at histological examination, and (c) quality of chelation treatment given before transplant. Patients with none of these adverse criteria were assigned to Class 1; patients with either one or two adverse criteria comprised Class 2; and patients for whom all three criteria were adverse constituted Class 3. Most patients older than 16 years have disease characteristics that place them in Class 3, with very few falling into Class 2. All patients with a histocompatibility leukocyte antigen (HLA)—identical donor are actually assigned to one of two conditioning regimens on the basis of the class they belong to at the time of BMT and independently of age. For Class 1, Class 2, and Class 3 patients, the probabilities of survival and event-free survival are 95 and 90%, 86 and 82%, and 87 and 63%, respectively. For those patients older than 16 years at the time of transplant, the probabilities of survival and of event-free survival are 78 and 74%, respectively. Allogeneic BMT is currently the only rational therapeutic modality for the eradication of β-thalassemia.
WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes.
Authors: Toshimi Takano, Hideharu Kimura, Kazuto Nishio, Takeharu Yamanaka, Yoshinori Ito, Junya Fukuoka, Junji Tsurutani, Yasushi Shigeoka, Masahiro Uehara, Kazuhiko Sato, Shinichiro Nakamura, Yoichi Nakanishi, Toshiaki Saeki
Journal: Journal of Clinical Oncology (2012)

TPS659 Background: In patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab and taxanes, there are now two standard strategies: trastuzumab beyond progression or switch to lapatinib. A randomized trial comparing trastuzumab plus capecitabine (HX) and capecitabine alone (X) after first-line trastuzumab-based chemotherapy (GBG-26) showed that HX was superior to X in terms of time to progression (TTP). Another randomized trial comparing lapatinib plus capecitabine (LX) and X in patients previously treated with anthracyclines, taxanes, and trastuzumab (EGF100151) showed that LX was superior to X in terms of TTP. To evaluate which strategy is better, we are conducting an open-label, randomized phase II trial comparing HX and LX. Methods: Primary endpoint is progression-free survival, and secondary endpoints are overall response rate, overall survival, proportion of patients progressing brain metastases as site of first progression, and safety. Major eligibility criteria include: (1) HER2-positive MBC, (2) previously treated with taxanes, (3) disease progression or distant relapse while receiving trastuzumab, (4) previously untreated with capecitabine, S-1, and anti-HER2 drugs other than trastuzumab, (5) previously treated with no more than two chemotherapy regimens for MBC, (6) no symptomatic brain metastases (asymptomatic brain metastases are allowed), and (7) baseline left ventricular ejection fraction ≥50%. Patients in the HX arm receive capecitabine 2,500 mg/m 2 /day on days 1 to 14 plus trastuzumab (8 mg/kg loading dose and 6mg/kg thereafter) on day 1 every 3 weeks. Patients in the LX arm receive capecitabine 2,000 mg/m 2 /day on days 1 to 14 plus lapatinib 1250 mg/day on days 1 to 21 every 3weeks. Large-scale biomarker analyses are also performed to explore predictive factors of trastuzumab or lapatinib efficacy. We are investigating biomarkers related to HER family and other receptors, PI3K/Akt pathways, ligands, FcγR, circulating tumor cells, and so on. This study has just begun and 7 of planned 170 patients have been enrolled.
Viral Hepatitis, Type A
Authors: Saul Krugman, Harriet Friedman, Cass Lattimer
Journal: New England Journal of Medicine (1975)

Hepatitis A antibody was detected by specific immune adherence and complement-fixation tests in a study involving 473 serum specimens from 20 patients who had viral hepatitis, Type A. In all 20 patients who had no detectable immune adherence antibody (< 1:5) before onset of hepatitis high levels (⪖ 1:1024) developed one to four weeks later, occasionally reaching peak levels exceeding ⪖ 1:81,920 several months thereafter. Five to 10 years later the immune adherence antibody levels ranged between 1:640 and 1:20,480. In general, the complement-fixation test was not as sensitive or as specific as the immune adherence test. These findings indicate that the immune adherence test should be a valuable tool for diagnosis, for epidemiologic surveys, for identification of susceptible and immune persons, for quantitative assays of gamma globulin and for identification of hepatitis A virus in attempts to propagate the virus in cell culture. (N Engl J Med 292:1141–1143 1975)
Integrated Analysis of IGHV Gene Status, Cell-of-Origin Signature and Genomic Features in Diffuse Large B-Cell Lymphoma
Authors: Pascaline Etancelin, Sydney Dubois, Pierre-Julien Viailly, Elodie Bohers, Philippe Bertrand, Philippe Ruminy, Catherine Maingonnat, Jean-Michel Picquenot, Sylvain Mareschal, Jean-Philippe Jais, Bruno Tesson, Pauline Peyrouze, Martin Figeac, Thierry Fest, Corinne Haioun, Thierry Lamy, Christiane Copie-Bergman, Bettina Fabiani, Richard Delarue, Frédéric Peyrade, André Marc, Nicolas Ketterer, Karen Leroy, Gilles A. Salles, Thierry Jo Molina, Hervé Tilly, Freda K Stevenson, Fabrice Jardin
Journal: Blood (2016)